Patents by Inventor Jon Amund Eriksen

Jon Amund Eriksen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NONAPEPTIDE WITH ANTI-TUMOUR ACTIVITY
    Publication number: 20110318364
    Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.
    Type: Application
    Filed: September 11, 2009
    Publication date: December 29, 2011
    Applicant: LYTIX BIOPHARMA AS
    Inventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
  • PEPTIDES
    Publication number: 20110105721
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Application
    Filed: January 3, 2011
    Publication date: May 5, 2011
    Applicant: GEMVAX AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Peptides
    Patent number: 7863244
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: January 4, 2011
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Antigenic peptides derived from telomerase
    Patent number: 7794723
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: September 14, 2010
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
  • POLYPEPTIDES
    Publication number: 20080187551
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Application
    Filed: March 5, 2008
    Publication date: August 7, 2008
    Applicant: GEM VAX AS
    Inventors: Gustav Gaudernack, Stein Saeboe-Larssen, Mona Moller, Jon Amund Eriksen
  • Polypeptides
    Patent number: 7375117
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: May 20, 2008
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Stein Sæøe-Larssen, Mona Møller, Jon Amund Eriksen
  • Peptides
    Patent number: 7192927
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: March 20, 2007
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
  • Polypeptides
    Patent number: 7078416
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: July 18, 2006
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
  • Antigenic peptides derived from telomerase
    Patent number: 7030211
    Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
    Type: Grant
    Filed: June 30, 1990
    Date of Patent: April 18, 2006
    Assignee: GemVax AS
    Inventors: Gustay Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
  • Immunogenic ?-amyloid peptide
    Patent number: 6861057
    Abstract: Frameshift Mutants ?-Amyloid precursor peptides and mutant ubiquitin-B associated with Alzheimer's disease and Down syndrome eliciting T cellular immunity for use in compositions for the treatment and/or prophylaxis of Alzheimer's disease and/or Down syndrome.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: March 1, 2005
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller
  • Peptides
    Patent number: 6759046
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.
    Type: Grant
    Filed: June 4, 2001
    Date of Patent: July 6, 2004
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
  • Polypeptides
    Publication number: 20040072759
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Application
    Filed: June 19, 2003
    Publication date: April 15, 2004
    Inventors: Gustav Gaudernack, Stein Saeboe-Larssen, Mona Moller, Jon Amund Eriksen
  • Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
    Publication number: 20030171266
    Abstract: Frameshift Mutants &bgr;-Amyloid precursor peptides and mutant ubiquitin-B associated with Alzheimer's disease and Down syndrome eliciting T cellular immunity for use in compositions for the treatment and/or prophylaxis of Alzheimer's disease and/or Down syndrome.
    Type: Application
    Filed: May 25, 2001
    Publication date: September 11, 2003
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller
  • Therapeutically useful peptides and peptide fragments
    Patent number: 5961978
    Abstract: Synthetic peptides and fragments of oncogene protein products which elicit T cellular immunity, for use in cancer vaccines and compositions for anti-cancer treatment.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: October 5, 1999
    Assignee: Norsk Hydro, a.s.
    Inventors: Gustav Gaudernack, Tobias Gedde-Dahl, Jon Amund Eriksen